Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -22.42%
• EPS Growth: 21.83%
• Country: IN
• Employees: 607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.88
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.04
• Price to Book (P/B): -1.17
• Price to Sales (P/S): 0.35
• P/FCF Ratio: -4.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: ―

The most significant factor in the low overall stock score is the company's severe financial distress, characterized by declining revenues, persistent losses, and high leverage with negative equity. The lack of technical analysis data further compounds the uncertainty surrounding the stock. Without valuation metrics and earnings call insights, the investment outlook remains highly unfavorable.

Positive Factors

Product Diversification

Vivimed Labs' diverse product offerings across pharmaceuticals and specialty chemicals provide multiple revenue streams, reducing dependency on a single market and enhancing resilience against sector-specific downturns.

Global Partnerships

Strategic alliances and collaborations with global firms enhance market reach and leverage R&D expertise, supporting long-term growth and competitive positioning in the pharmaceutical sector.

R&D Expertise

Vivimed Labs' focus on R&D and strategic alliances positions it to innovate and adapt to industry changes, ensuring sustained competitive advantage and potential for new product development.

Negative Factors

Financial Distress

Persistent losses, high leverage, and negative equity indicate significant financial instability, posing risks to operational continuity and necessitating urgent restructuring for long-term viability.

Revenue Decline

Consistent revenue decline suggests challenges in market competitiveness and demand, potentially impacting future growth prospects and necessitating strategic changes to reverse the trend.

Cash Flow Challenges

Negative free cash flow and volatile operating cash flow indicate cash management issues, threatening the company's ability to sustain operations and invest in growth opportunities.

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Vivimed Labs Limited (VIVIMEDLAB) is a global pharmaceutical and specialty chemicals company based in India. The company operates primarily in the sectors of pharmaceuticals, personal care, and specialty chemicals, offering a diverse range of products including active pharmaceutical ingredients (APIs), formulations, and high-value intermediates. Vivimed Labs focuses on providing innovative solutions in healthcare and beauty, catering to both domestic and international markets.

How the Company Makes Money

Vivimed Labs generates revenue through multiple streams, primarily by manufacturing and selling active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves a wide array of clients, including major pharmaceutical companies and contract manufacturers, which form a significant part of its customer base. Additionally, Vivimed Labs has established partnerships and collaborations with various organizations to enhance its product offerings and expand its market reach. The revenue model is further supported by its specialty chemicals segment, which provides high-value products for personal care and industrial applications. The combination of these revenue streams, along with strategic alliances and a strong global presence, contributes to the company's overall earnings.

Vivimed Labs Limited Financial Statement Overview

Summary

Vivimed Labs Limited faces severe financial distress across all verticals. The income statement reflects declining revenues and persistent losses, while the balance sheet shows high leverage with negative equity, raising questions about the company's solvency. Cash flow challenges further exacerbate the situation, with negative free cash flow and inconsistent operating cash flow. The company needs substantial restructuring and strategic changes to stabilize its financial position and return to growth.

Income Statement

The income statement reveals significant challenges, with consistent revenue decline and negative profit margins. Gross profit margin dropped sharply over the years, and the company has reported negative EBIT and net income for consecutive years. This indicates a struggling operational efficiency and severe profitability issues, with no signs of immediate improvement.

Balance Sheet

The balance sheet demonstrates a concerning financial position. The debt-to-equity ratio is not calculable due to negative equity, indicating insolvency risk. Additionally, the company's total liabilities exceed its total assets, presenting a critical leverage issue. The return on equity (ROE) is also not calculable due to negative equity, further highlighting financial instability.

Cash Flow

The cash flow statement highlights substantial negative free cash flow, though there was a brief period of positive operating cash flow in 2023. The company's operating cash flow and free cash flow remain volatile and insufficient to cover operating expenses, indicating cash management concerns and sustainability issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.43B	1.16B	1.49B	1.87B	2.37B	8.61B
Gross Profit	508.66M	77.98M	705.71M	-928.65M	838.04M	5.07B
EBITDA	-353.93M	-86.77M	-246.69M	-1.86B	-67.91M	336.05M
Net Income	-463.30M	-319.61M	-454.46M	-3.29B	-676.50M	-777.95M
Balance Sheet
Total Assets	0.00	9.21B	9.51B	9.88B	12.66B	12.89B
Cash, Cash Equivalents and Short-Term Investments	16.26M	7.08M	717.79M	37.62M	71.84M	64.31M
Total Debt	0.00	3.76B	3.79B	3.81B	2.78B	2.53B
Total Liabilities	54.61M	9.56B	9.56B	9.49B	9.02B	8.58B
Stockholders Equity	-54.61M	-351.69M	-54.61M	394.23M	3.64B	4.32B
Cash Flow
Free Cash Flow	188.16M	-86.28M	-260.30M	303.54M	-6.75B	5.67B
Operating Cash Flow	188.16M	-40.97M	-239.91M	138.12M	-6.58B	5.67B
Investing Cash Flow	0.00	-45.31M	282.88M	-49.68M	5.23B	4.04B
Financing Cash Flow	0.00	73.10M	-60.32M	-162.44M	-103.80M	-10.15B

Vivimed Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	62 Neutral	₹419.58M	10.47	―	―	―	―
BIOFILCHEM	55 Neutral	₹644.44M	23.02	―	―	36.76%	433.63%
INDSWFTLTD	53 Neutral	―	―	―	―	2.59%	1891.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	43 Neutral	₹585.18M	-1.77	―	―	-20.40%	-59.20%
VIVIMEDLAB	37 Underperform	―	―	―	―	-22.42%	21.83%

Vivimed Labs Limited Corporate Events

Vivimed Labs’ Debt Assigned to Rare Asset Reconstruction Ltd.

Vivimed Labs Limited has announced that Rare Asset Reconstruction Ltd. has acquired the company’s financial assets from the State Bank of India. This transfer includes all underlying security interests, rights, and obligations, allowing Rare ARC to recover dues from Vivimed Labs, impacting the company’s financial restructuring and stakeholder obligations.

Vivimed Labs Reports Financial Results Amid Loan Default Challenges

Vivimed Labs Limited’s Board of Directors approved several key resolutions in their recent meeting, including the submission of unaudited financial results for the quarter ending June 30, 2025, and the re-appointment of key directors and auditors. Despite these developments, the company faces financial challenges, with a significant default in loan repayments amounting to Rs 3,748.22 million, leading to all loan accounts being classified as non-performing assets by banks. This financial strain could impact the company’s operational stability and stakeholder confidence.